Holen Sie sich die Stockscreener-App
10.72
3.68%
0.38
Schlusskurs vom Vortag:
$10.34
Offen:
$10.43
24-Stunden-Volumen:
2.66M
Relative Volume:
2.23
Marktkapitalisierung:
$854.98M
Einnahmen:
$204.89M
Nettoeinkommen (Verlust:
$-157.30M
KGV:
-5.0779
EPS:
-2.1111
Netto-Cashflow:
$-97.76M
1W Leistung:
-1.47%
1M Leistung:
-3.42%
6M Leistung:
-38.95%
1J Leistung:
+12.25%
1-Tages-Spanne:
$10.11
$10.78
1-Wochen-Bereich:
$10.02
$11.16
52-Wochen-Spanne:
$7.61
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
10.72 | 854.98M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-12 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT) - TradingView
PHAT Forecast — Price Target — Prediction for 2027 - TradingView
Phathom Pharmaceuticals supports upcoming GI meetings as industry engagement expands - Traders Union
Phathom Pharmaceuticals details new Voquezna launch pace, shares track gastro health focus - Ad-hoc-news.de
Phathom Pharmaceuticals Inc (PHAT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating - Moomoo
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phathom Pharmaceuticals (PHAT) Completes Enrollment in Clinical Trial - GuruFocus
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study - Investing.com UK
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com - Investing.com Nigeria
Phathom Completes Enrollment in Eosinophilic Esophagitis Trial - TipRanks
Phathom completes enrollment in vonoprazan trial for EoE By Investing.com - Investing.com Australia
Phathom Pharmaceuticals Completes Enrollment in Phase 2 VOQUEZNA Clinical Trial for Eosinophilic Esophagitis, Results Expected Q4 2026 5 – Minichart - Minichart
Phathom completes enrollment in vonoprazan trial for EoE - Investing.com
Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026 - Stock Titan
Phathom enrolls 95 adults in VOQUEZNA EoE trial; results due in Q4 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven? - 富途牛牛
Phathom Pharmaceuticals Inc (PHAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PHAT Stock Price, Quote & Chart - ChartMill
Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Buy on Phathom stock, $26 target By Investing.com - Investing.com Canada
Behavioral Patterns of PHAT and Institutional Flows - Stock Traders Daily
Phathom Pharmaceuticals (PHAT) Surges 4.74% as Bullish Momentum BuildsBreakout Trade - newsline.com
Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Phathom Pharmaceuticals scheduled for 2:40 PM fireside chat at major healthcare event - Traders Union
Phathom: Why I’m Downgrading To "Sell" Ahead Of Competition (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference - Traders Union
(PHAT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Phathom Pharmaceuticals honors Tachi Yamada legacy in GI medicine - Traders Union
Phathom Pharmaceuticals (PHAT) Surges 4.44% as Stock Tests Key ResistanceWave Alternation - newsline.com
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs. - Pluang
[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Phathom Pharmaceuticals to engage investors at multiple conferences in May and June - Traders Union
How (PHAT) Movements Inform Risk Allocation Models - Stock Traders Daily
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Phathom Pharmaceuticals (PHAT) Slips 2.16% as Stock Tests Key Support LevelsOBV Divergence - thelegaladvocate.com
Hear Phathom at three upcoming healthcare investor conferences - Stock Titan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):